{"id":55635,"date":"2022-07-28T18:00:02","date_gmt":"2022-07-28T18:00:02","guid":{"rendered":"https:\/\/merryjane.com\/dea-decides-not-to-ban-five-new-psychedelic-research-chemicals\/"},"modified":"2022-07-28T18:00:02","modified_gmt":"2022-07-28T18:00:02","slug":"dea-decides-not-to-ban-five-new-psychedelic-research-chemicals","status":"publish","type":"post","link":"https:\/\/merryjane.com\/news\/dea-decides-not-to-ban-five-new-psychedelic-research-chemicals\/","title":{"rendered":"DEA Decides Not to Ban Five New Psychedelic “Research Chemicals”"},"content":{"rendered":"

In a surprise decision, the US Drug Enforcement Agency just announced that it will back down<\/u><\/a> on its plans to ban five novel psychedelics.<\/p>\n

The DEA originally kicked off its plan to ban<\/u><\/a> 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT at the start of 2022. In January, the agency posted a notice in the Federal Register stating their intent to classify all five of these relatively unexplored psychedelic tryptamines as Schedule I drugs. The notice argued that these drugs should immediately be banned because they are \u201cbeing abused for their hallucinogenic properties.\u201d<\/p>\n

The category of Schedule I drugs is exclusively reserved for deadly, addictive drugs with no medical value. The DEA notice did not provide conclusive proof that either of these criteria had been met, though. As evidence of the drugs’ supposed dangers, the feds were only able to identify a couple cases where people were briefly hospitalized after taking two of these five psychedelics, and one case where someone died after ingesting 5-MeO-AMT along with a cocktail of other drugs. And because the compounds are not yet well-researched, their potential medical value has yet to be established. <\/p>\n